Timely research papers about COVID-19 in Chinadoi:10.1016/S0140-6736(20)30375-5Yu-Tao XiangWen LiQinge ZhangYu JinBrian J HallThe Lancet
As of June 18, COVID-19 has hit over 210 countries and regions, affected more than seven billion people around the world and claimed over 440,000 precious lives. The virus does not respect borders. Nor is race or nationality rel...
this study (Supplement 3). The two reviews18,19 both concluded that acupuncture could improve the symptoms of COVID-19 patients, and one of which found that acupuncture could also relieve the negative emotions to improve the health status.18 More details about the two reviews are in Table 3...
Find latest Updates and News on COVID19, Global Market Research Report with detailed Forecasts and COVID19 Pipeline Drugs
Research Report: How COVID-19 has disrupted employee work life, safety and their perception of employers
This new Covid-19 belongs to the coronavirus family , which includes SARS (2003) and MERS-Cov (2012). The Covid-19 viral genome encodes several proteins with unique functions, including Spike protein, N protein and M protein. The two main proteins of pharmaceutical interest ...
and a study on COVID-19 origins based on big data modeling, which was published on Sept. 22 this year on ChinaXiv, an online pre-print platform operated by the Chinese Academy of Sciences. The studies indicated that for 12 northeastern U.S. states, the possible dates of the first infecti...
Camostat mesylate, the drug used in this study to inhibit TMPRSS2, is approved for clinical use to treat other conditions, but its safety and efficacy in COVID-19 patients is not yet known. 2. Replicase Assembly The life cycle of the original SARS-CoV, many aspects of which are likely...
Since the emergence of COVID-19, a great deal of research has been carried out to determine the structure of the virus and the mechanisms of infection and replication. Key points in the lifecycle have subsequently been identified as potential prophylactic or therapeutic targets. SARS-CoV-2 is ...
Therefore, we considered the period between March 15, 2020 and July 15, 2020 as the early COVID-19 pandemic duration. We further extended the analysis to study the trend later in the pandemic and compared healthcare encounters, procedures, and diagnoses of new GI cancers at participating HCOs...